Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC)

NCT06127238 is registered in ClinicalTrials.gov with Beijing Scitech-Mq Pharmaceuticals Limited as lead sponsor.

NCT NCT06127238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06127238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC)
Lead sponsor
Beijing Scitech-Mq Pharmaceuticals Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 7, 2023
Completion date
December 31, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma